Ascletis Pharma Inc Total Liabilities

Latest as of December 2025: €132.26 Million EUR ≈ $154.63 Million USD

Ascletis Pharma Inc total liabilities. Based on the latest financial reports, Ascletis Pharma Inc (2VJ) has total liabilities worth €132.26 Million EUR (≈ $154.63 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 2VJ cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Ascletis Pharma Inc (2016–2025)

Total liabilities of Ascletis Pharma Inc from 2016 to 2025. This chart illustrates how Ascletis Pharma Inc's total liabilities have evolved over time, based on quarterly financial data.

Ascletis Pharma Inc Competitors by Total Liabilities

The table below lists competitors of Ascletis Pharma Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Ooh!Media Ltd AU:OML	Australia	AU$1.17 Billion
Tianjin Jiuri New Materials Co Ltd SHG:688199	China	CN¥1.49 Billion
Performant Healthcare, Inc NASDAQ:PHLT	USA	$28.72 Million
Just Dial Limited NSE:JUSTDIAL	India	Rs9.38 Billion
ChemPartner PharmaTech Co Ltd SHE:300149	China	CN¥728.59 Million
Arafura Rare EARTHS Ltd AU:ARU	Australia	AU$21.96 Million
Forge Global Holdings Inc NYSE:FRGE	USA	$45.63 Million
ESGL Holdings Limited NASDAQ:OIO	USA	$12.20 Million

Liability Composition Analysis (2016–2025)

This chart breaks down Ascletis Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Ascletis Pharma Inc balance sheet assets.

Liquidity & Leverage Metrics

Ascletis Pharma Inc Total Liabilities Ratios Explained

Ascletis Pharma Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	15.05	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.07	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.06	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Ascletis Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Ascletis Pharma Inc (2016–2025)

The table below shows the annual total liabilities of Ascletis Pharma Inc from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	€132.26 Million ≈ $154.63 Million	-16.51%
2024-12-31	€158.41 Million ≈ $185.20 Million	+6.36%
2023-12-31	€148.94 Million ≈ $174.13 Million	+27.13%
2022-12-31	€117.16 Million ≈ $136.97 Million	+16.13%
2021-12-31	€100.89 Million ≈ $117.95 Million	+18.10%
2020-12-31	€85.42 Million ≈ $99.87 Million	-16.39%
2019-12-31	€102.17 Million ≈ $119.45 Million	+1.98%
2018-12-31	€100.19 Million ≈ $117.13 Million	-17.49%
2017-12-31	€121.42 Million ≈ $141.96 Million	-4.53%
2016-12-31	€127.18 Million ≈ $148.69 Million	--

About Ascletis Pharma Inc

F:2VJ Germany Biotechnology

Market Cap

$623.07 Million

€532.95 Million EUR

Market Cap Rank

#10794 Global

#1268 in Germany

Share Price

€0.51

Change (1 day)

-6.48%

52-Week Range

€0.47 - €1.99

All Time High

€1.99